Pipeline

ADG106

ADG106: Novel agonistic anti-CD137 NEObody™ candidate

Our lead NEObody™ candidate, ADG106, is a fully human ligand-blocking, agonistic anti-CD137 Immunoglobulin G4, or IgG4, mAb, being developed for the treatment of advanced solid tumors and non-Hodgkin’s lymphoma, or NHL. CD137 stimulates the immune system to attack cancer cells and is a key driver for long-lasting T-cell proliferation and survival. In both clinical and preclinical studies to date, we observed that ADG106 had robust antitumor activity and was well tolerated as a single agent and in combination with the existing standard-of-care and other immuno-oncology therapies. ADG106 was observed to balance between CD137-induced toxicity and CD137 agonism, which we believe has potential to address the limitations of other existing anti-CD137 therapies.

ADG106 is in ongoing Phase 1b/2a clinical trials in patients with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin’s lymphoma.